

Date: February 01, 2024

BSE Limited
P J Towers,
Dalal Street,

Mumbai – 400 001

**National Stock Exchange of India Limited** 

Exchange Plaza, C-1, Block G, Bandra Kurla Complex,

Bandra (E), Mumbai – 400 051

Symbol: MANKIND

Dear Sir/ Madam,

Script Code: 543904

Subject: Newspaper Publication of Consolidated Unaudited Financial Results for the quarter and nine months ended December 31, 2023

Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith extracts of the Consolidated Unaudited Financial Results for the quarter and nine months ended December 31, 2023 as published in "Financial Express" and "Jansatta" on February 01, 2024.

You are requested to kindly take the above information on your records.

Thanking You,

Yours Faithfully,

For Mankind Pharma Limited

Pradeep Chugh Company Secretary and Compliance Officer Membership No. A18711 **FINANCIAL EXPRESS** 

# **BOOST FROM A HEALTHY LOAN GROWTH**

# BoB beats profit estimates in Q3

Shares hit 52-week high in the day

**SACHIN KUMAR** Mumbai, January 31

BANK OF BARODA on Wednesday reported an 18.8% rise in net profit to ₹4,579 crore in the third quarter of current financial year, aided by a healthy loan growth.The public sector lender beat expectations as Bloomberg analysts expected the bank to post ₹4,127 crore net profit in the quarter.

Net interest income, the difference between interest earned and paid, rose 2.6% to ₹11,101 crore from ₹10,818 crore a year ago. Net interest margin (NIM) contracted to 3.23% compared to 3.54% a year ago.

"Going forward, in January-March, generally we see a lot of traction in terms of deposit growth. We had given a guidance of 12-14% growth for deposits and we hope to maintain around 12% deposit growth to maintain advances growth of 14-16%," said Debadatta Chand, MD & CEO, Bank of Baroda, in an earnings call on Wednesday.

The bank improved its asset quality during the quarter as gross non-performing assets

**RBI Digital** 


**Payments** 

September

**FE BUREAU** 

Index rises in

REPORT CARD



(NPAs) declined to 3.08% of gross loans by the end of December 2023 from 4.53% a vearago. Similarly, net NPAs or bad loans came down to 0.70% from 0.99% a year ago.

However, the bank's capital adequacy ratio moderated to 14.72% against 14.93% at the end of December 2022.

During the December quarter of FY24, the bank made a contingent provision of ₹50.49 crore in respect to its investment in alternate investment fund (AIF) pursuant to an RBI circular dated December 19, 2023.

The lender witnessed a December end.

The bank managed to

three times of slippages. Total

slippages were at ₹4,551 crore

we will set a target that what-

ever will be the slippages,

recovery should be double that

amount because we are having

so much of stock — ₹60,000

crore is gross NPA," said Atul

Kumar Goel, managing direc-

tor and chief executive officer,

recovery was higher than slip-

pages, he added. Total slip-

pages in the third quarter of

FY24 stood at ₹1,793 crore

while recoveries were at

taken various measures to

boost its recovery, and is not

entirely depending on the

Goel said the bank has

In the third quarter also, the

"For the next financial year,

during the period.

in an earnings call.

₹6,387 crore.

strong loan growth as its domestic advances increased by 13.4% year-on-year to ₹8.62 trillion as of December 31, 2023, while global advances grew 13% to ₹10.49 trillion. Domestic deposits increased by 6.3% to ₹10.67 trillion while international deposits grew

22.1% to ₹1.77 trillion.

Close

Open

Retail advances grew by 22%, led by growth in auto loan, home loan, personal loan, mortgage loan and education loan. Corporate advances registered a growth of 10.2% to reach ₹3.62 trillion as of

# Banks' credit growth slows to 20% in December

**FE BUREAU** Mumbai, January 31

**BANKS' NON-FOOD CREDIT** grew 20.1% year-on-year (y-oy) to ₹159.18 trillion as of December 29, lower than 21% in November, RBI's sectoral deployment of credit data showed. Excluding the merger impact of HDFC twins, credit offtake was up 16%.

Bank credit to agriculture and allied activities was up nearly 20% y-o-y to ₹19.94 trillion in December, higher than 12% a year ago, while credit to industry segment rose 9% y-o-y to ₹36.64 trillion. Within the industry segment, credit to large corporates rose 7% y-o-y to ₹26.70 trillion.

Among the services sector, loans to NBFCs rose 15% to ₹15.20 trillion, sharply lower than the 34% y-o-y growth a year ago. This gains importance as the RBI had in November hiked risk weights on bank loans to NBFCs by 25% over and above the risk weight associated with the given external rating in all cases where the risk weight was below 100%.

RBI had also hiked risk weight on unsecured consumer credit, including credit card loans to 125% from 100%. However, data showed that while consumer durable loans' growth moderated to 14% y-oyto ₹24,312 crore in December from 28% a year ago.

# Recoveries may be double of slippages in FY25: PNB

**SACHIN KUMAR** 

Mumbai, January 31 THE RESERVE BANK of India (RBI) Digital Payments Index financial year. The higher recovrose to 418.77 in September

ery target comes amid encour-2023 from 395.57 in March 2023, according to a press aging recoveries made by the release on Wednesday. lender in the current fiscal. Since January 2021, RBI has been publishing a composite recover ₹15,881 crore from bad loans for the first nine digital payments index with months of FY24, which is over March 2018 as base to capture

the extent of digitisation of payments across the country. The index stood at 377.46 in September 2022. "The RBI-DPI index has increased across all parameters

and was driven particularly by growth in payment enablers, payment performance and consumer centricity across the country over the period." the press release said.

The index comprises five parameters that enable measurement of deepening and penetration of digital payments in the country over different time periods. These parameters are payment enablers, payment infrastructure — demand-side factors, payment infrastructure supply-side factors, payment performance, and consumer centricity.

THE STORY SO FAR Mumbai, January 31

₹ 15,881 crore PUNJAB NATIONAL BANK (PNB) is expecting recoveries recovery in first nine from bad loans to double the months of FY24 slippages amount in the next

₹ 4,551 crore Total slippages in first nine months of FY24

Total slippages in Q3 ₹ 6,387 cr recoveries in Q3

₹ 1,793 cr

₹ 1,831 cr

recovery from NCLT of the total in Q3

₹5,533 cr recovered in Q2

₹1,826 cr slippages in Q2

National Company Law Tribunal (NCLT) for the same.

"Recovery from the NCLT is just one-third of total recoveries. Out of ₹6,387 crore which we recovered in the December quarter, the recovery from the NCLT was only

₹1,831 crore," Goel said. The bank maintained the trend of higher recovery in the second quarter as well. It recovered ₹5,533 crore in the July-September period while slip-

pages stood at ₹1,826 crore. Apart from boosting its recovery, the state-run lender

has also been able to improve its asset quality.

Its gross non-performing

assets (GNPA) ratio improved

by 352 basis points year-on-

year to 6.24% as on December 2023, from 9.76% in the yearago period. The NNPA ratio improved by 234 bps on a y-o-y basis to

0.96% from 3.30%. Gross NPAs stood at ₹60,371 crore

against ₹65,563.1 crore in the previous quarter, while net NPAs came in at ₹8,815.8 crore, compared with ₹13,114 crore.

## Sun Pharmaceutical Industries Limited Regd Office: SPARC, Tandalja, Vadodara - 390012, Gujarat, INDIA

Corporate Office: Sun House, Plot No. 201 B/1, Western Express Highway, Goregoan (E), Mumbai - 400063

Tel No. +91 22 43244324 CIN: L24230GJ1993PLC019050 Website: www.sunpharma.com

Extract of Unaudited Consolidated Financial Results for the Quarter and Nine Months ended December 31, 2023 Year ended Quarter ended Nine Months ended **Particulars** 31.12.2023 30.09.2023 31.12.2022 31.12.2023 31.12.2022 31.03.2023 Unaudited Unaudited Unaudited Unaudited Unaudited Audited 123,807.0 121,924.1 112,409.7 365,139.5 329,550.1 438,856.8 Total revenue from operations 86,650.5 95,798.8 Profit / (Loss) for the period 30,701.6 27,908.8 24,714.7 71,687.4 (before Tax, Exceptional items) Profit / (Loss) for the period before tax 27,908.8 24,714.7 82,723.7 94,084.3 30,003.5 71,687.4 (after Exceptional items) 23,755.1 21,660.1 84,735.8 Net Profit / (loss) after taxes, share of profit / 25,237.5 69,218.0 64.891.1 (loss) of associates and joint venture and non-controlling interests Total Comprehensive Income for the period 29,854.8 26,043.5 29,291.4 78,121.5 89,475.3 107,695.1 [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)] 2,399.3 Equity Share Capital 2,399.3 2,399.3 2,399.3 2,399.3 2,399.3 557,554.5 Other Equity N.A. N.A. N.A. N.A. N.A. Earnings Per Share (of ₹ 1/- each) (not annualised for quarters) 27.0 35.3 10.5 9.9 9.0 28.8 ₹ Basic: 27.0 35.3 ₹ Diluted: 9.9 9.0 28.8 10.5

Notes: The above unaudited consolidated financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on January 31, 2024.

Additional information on standalone financial results is as follows: (₹ in Million) Nine Months ended Quarter ended Year ended 31.12.2023 31.03.2023 30.09.2023 31.12.2022 31.12.2023 31.12.2022 **Particulars** Unaudited Unaudited Unaudited Unaudited Unaudited Audited Total revenue from operations 208,121.4 50,737.5 50,962.1 46,457.5 146,360.3 148,639.2 Profit/(loss) for the period (before Tax) 9,065.2 7.514.7 5,060.8 20,478.7 27,713.2 17,410.5 (after Exceptional items) Net Profit /(loss) for the period (after tax) 19,905.8 27,115.4 16,907.2 7,213.1 8.886.3 4.867.3 Total Comprehensive Income for the period 7,275.7 8,550.1 4,993.3 19,865.6 26,595.9 16,797.1 [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]

3. The above is an extract of the detailed format of unaudited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the unaudited Financial Results are available on the websites of the Stock Exchanges i.e. www.bseindia.com and www.nseindia.com and on the Company's website www.sunpharma.com

For and on behalf of the Board Dilip S. Shanghvi Managing Director

# FROM THE FRONT PAGE

# Import duty on mobile phone parts slashed

The import duty on inputs or parts that are used in manufacturing of these components has been reduced to nil from 7.5% and 15%.

"This rationalisation of customs duties brings muchneeded certainty and clarity for the industry and in the customs processes," communications and IT minister Ashwini Vaishnaw said. "I thank the Prime Minister and the finance minister for this step towards strengthening the mobile phone manufacturing ecosystem," he added.

Minister of state for electronics and IT Rajeev Chandrasekhar said: "Competitiveness and scale are critical to India's transformation into a global hub for electronics manufacturing and exports, and pivot into export-led manufacturing."

According to a study by the India Cellular and Electronics Association (ICEA), higher tariffs in India result in an overall loss of competitiveness of about 6% to 7% compared with Vietnam and China.

The mobile phone and electronics companies welcomed the announcement.

"The adjustment of BCD (basic customs duty) to 10% on parts of mobile phones and mechanics and die-cut parts and 0% on inputs of mechanics represents the start of a paradigm shift in the policy orientation of the government towards export-led growth and competitiveness," said Pankaj Mohindroo, chairman at ICEA. Electronics industry associa-

tion MAIT echoed the view, stating that the duty reduction will improve the competitiveness of India in the global market.

"The duty cut can help drop smartphone prices by 3-5%, empowering the consumers and making the devices affordable, especially in the entry and budget segments," Tarun Pathak, research direcASHWINI VAISHNAW, IT MINISTER

THIS RATIONALISATION **OF DUTIES BRINGS** MUCH-NEEDED **CERTAINTY AND CLARITY** FOR THE **INDUSTRY AND** IN THE CUSTOMS **PROCESSES** 

RAJEEV CHANDRASEKHAR. MoS FOR ELECTRONICS & IT



According to market tracker firm International

Data Corp (IDC), the average selling price (ASP)of smartphones in India hit a high of \$253 (₹21,000), with 5% sequential and 12% on-year growth in the July-September quarter. Navkender Singh, associate

vice-president at IDC India, said: "Looking at the current list, very few basic components seem to be covered. Hence, the end pricing can be slashed anywhere in range of 1-2%, or more realistically, this would not impact the consumer pricing at all."

Faisal Kawoosa, chief analyst at Techarc, said: "OEMs (original equipment makers) might not be keen to pass the cost reduction to end consumers. Rather, they would use this either in increasing channel margins or using it somewhere else."

In 2018, the basic customs duty on mobile phone components in other categories was raised by the government to 15% from 5% under the Phased Manufacturing Programme (PMP). The same led to issues of misinterpretations and created inadvertent complications for the mobile phone industry.

However, trade body Global Trade Research Initiative (GTRI) was critical of the move to reduce the import duties. "The duty cut will have no impact on improving export competitiveness of mobile phones made in India as all inputs, parts, and components used in the making of mobile phones for exports can already be imported at zero duty under various government schemes like SEZ (special economic zone) and Advance authorisation," it said.

The think tank said firms like Apple are already using these schemes. Apple has partnered with contract manufacturers like Foxconn, Pegatron and Tata-owned Wistron to make iPhones in the country.

Currently, mobile phones constitute over 52% of electronics exports. The continuous improvement is owing to the impact of the productionlinked incentive (PLI) scheme. India's smartphone exports

jumped 100% in FY23 to \$11 billion (₹90,000 crore) over FY22. The industry expects exports of \$15 billion (around ₹1.2 trillion) in FY24, largely led by Samsung and Apple. Exports will form 30% of the total production of \$49-50 billion (around ₹4.1 trillion) in the current financial year ending March.

# Wipro to lay off hundreds of staff

The spokesperson further said the IT services firm is committed to investing in people, processes and technology to drive better client and employee experiences and enhance productivity and agility across the organisation to meet fast-evolving client and market needs.

The challenge before Wipro chief executive officer Thierry Delaporte is to balance margin and growth.

Wipro's margins came in at 16% during the October-December quarter. Tata Consultancy Services, Infosys and HCLTech reported margins of 25%, 20.5% and 19.8%, respectively.

Sources said that Wipro is working big time on automation and has committed to invest \$1 billion on artificial intelligence (AI) technologies over the next three years. It has launched an AI-first innovation ecosystem, Wipro ai360, to integrate AI into every platform, tool and solution used internally and offered to its clients.

"We are aligning our operational structure, skilling academies and GenAI capabilities to market demand client expectations and also to the evolving process landscape inside Wipro. We are one of the biggest customers of our ai 360 ecosystem. These transformation programmes and margin expansion initiatives are delivering results," Wipro chief operating officer Amit Choudhary had said during the Q3 earnings call.

"Our goals remain profitable growth, delivery excellence and internal capability development, all leading towards sustainable success."

Choudhary had added:



# MANKIND PHARMA LIMITED

Registered Office: 208, Okhla Industrial Estate, Phase-III, New Delhi - 110 020, Delhi, India; Tel.: +91 11 4747 6600 Corporate Office: 262, Okhla Industrial Estate, Phase-III, New Delhi - 110 020, Delhi, India; Tel.: +91 11 4684 6700 Email: investors@mankindpharma.com, Website: www.mankindpharma.com, CIN: L74899DL1991PLC044843

Extract of unaudited financial results for the quarter and nine months ended December 31, 2023

(₹ in Lacs except as stated otherwise)

				Consol	lidated			
S. No.	Particulars	Fo	r the quarter en	ded	For the nine r	For the		
		31.12.2023 (Unaudited)	30.09.2023 (Unaudited)	31.12.2022 (Unaudited)	31.12.2023 (Unaudited)	31.12.2022 (Audited)	Year ended 31.03.2023 (Audited)	
1	Revenue from operations	260,695.89	270,809.90	209,093.03	789,367.54	669,676.60	874,943.30	
2	Profit for the period/year before tax	56,232.92	64,098.71	37,898.93	182,778.18	129,395.38	167,123.91	
3	Profit for the period/year after tax	45,981.37	51,117.67	29,571.95	146,517.88	101,597.76	130,967.58	
4	Total comprehensive income for the period/ year	46,556.60	50,905.98	29,382.74	146,551.79	101,019.09	130,778.83	
5	Paid-up equity share capital	N.A.	N.A.	N.A.	N.A.	N.A.	4,005.88	
6	Other equity excluding revaluation reserve	N.A.	N.A.	N.A.	N.A.	N.A.	739,516.40	
7	Earnings per equity share of face value of ₹ 1/- each	11.33	12.51	7.09	35.99	24.87	32.00	
	- Basic EPS (in ₹) - Diluted EPS (in ₹)	11.31 (Not annualised)	12.49 (Not annualised)	7.09 (Not annualised)	35.94 (Not annualised)	24.87 (Not annualised)	32.00	

The key standalone financial information is as under: (₹ in Lacs except as stated otherwise)									
S.	Particulars	Fo	r the quarter er	nded	For the nine i	For the Year ended			
No.		31.12.2023 (Unaudited)	30.09.2023 (Unaudited)	31.12.2022 (Unaudited)	31.12.2023 (Unaudited)	31.12.2022 (Audited)	31.03.2023 (Audited)		
1	Revenue from operations	235,856.62	245,334.52	193,623.10	711,212.27	625,503.15	812,715.32		
2	Profit for the period/year before tax	57,635.16	61,196.24	32,563.69	171,470.71	120,740.31	156,283.66		
3	Profit for the period/year after tax	48,707.33	47,288.44	24,887.32	136,923.99	96,727.00	124,825.80		
4	Total comprehensive income for the period/year	49,399.98	46,932.51	24,606.02	136,991.74	95,870.94	124,339.91		

Place: New Delhi

Date: January 31, 2024

The above is an extract of the detailed format of Quarterly Unaudited Consolidated and Standalone Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Reguirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Stock Exchanges website: www.bseindia.com and www.nseindia.com and also on the Company's website: www.mankindpharma.com.

The Unaudited Consolidated and Standalone Financial Results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on January 31, 2024.

New Delhi

MANKIND PHARMA LIMITED

For and on behalf of

Ramesh Juneja Chairman and Whole Time Director DIN: 00283399

Mumbai, January 31, 2024 financialexp.epap



Continued from previous page

The Board of Directors of the Company at its meeting held on January 31, 2024 has taken on record the Basis of Allotment of Equity Shares, as approved by the Designated Stock Exchange viz. NSE Emerge and has authorized the online corporate action for the allotment of the Equity Shares in dematerialised form to various successful applicants. The CAN-cum-Refund Orders and Allotment Advice and/or Notices are being dispatched to the address of the applicants as registered with the depositories / as filled in the application form on February 01, 2024. Further, the instructions to Self-Certified Syndicate Banks being processed on January 31, 2024 for unblocking fund. In case the same is not received in compliance with the applicable timeline, investors may contact at the address given below. The Equity Shares allocated to successful applicants are being credited to their beneficiary accounts subject to validation of the account details with the depositories concerned. The company shall file the listing application with NSE Limited on or before February 01, 2024. The Company is in process of obtaining the listing & the trading approval from NSE Limited and the trading is expected to commence on February 02, 2024.

Note: All capitalised terms used and not specifically defined herein shall have the same meaning as Ascribed to them in the Prospectus dated January 18, 2024.

DISCLOSURES PERTAINING TO THE LM'S TRACK RECORD ON PAST ISSUES WITH A BREAKUP OF HANDLING OF SME IPOS FOR THE LAST 3 YEARS: FEDEX SECURITIES PRIVATE LIMITED

TYPE	FY 2020-21	FY 2021-22	FY 2022-23
SME IPO	2	5	7
MAIN BOARD	0	0	0

#### INVESTORS, PLEASE NOTE

The details of the allotment made would also be hosted on the website of the Registrar to the Issue, Bigshare Services Private Limited at ipo@bigshareonline.com. All future correspondence in this regard may kindly be addressed to the Registrar to the Issue quoting full name of the first/ sole applicants, serial number of the application form, number of shares applied for and Bank Branch where the application had been lodged and payment details at the address of the Registrar given below:



BIGSHARE SERVICES PRIVATE LIMITED Office No. S6 - 2, 6th Floor, Pinnacle Business Park, Next to Ahura Centre, Mahakali Cave Road, Andheri - [East], Mumbai - 400093, Maharashtra, India. Tel No: +91 22 6263 8200

Fax No: +91 22 6263 8299 E-mail Id: ipo@bigshareonline.com Website: www.bigshareonline.com Contact Person: Mr. Aniket Chindarkar SEBI Registration No: INR000001385

# INVIGORATED BUSINESS CONSULTING LIMITED

(Formerly Escorts Finance Limited)

EXTRACT OF STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2023

CIN: L74110CH1987PLC033652 Regd. Office: Plot No. 19, Industrial Area, Phase 2, Chandigarh - 160002

Phone: 0129-2564116, E-mail: escortsfinance@escortsfinance.com, Website: www.escortsfinance.com

01		Quarter ended	Nine Months ended	Quarter ended
SI. No.	Particulars	31.12.2023	31.12.2023	31.12.2022
		(Unaudited)	3 31.12.2023 ) (Unaudited) 21.20 (12.42) (12.42) (12.42) (12.42) (12.42)	(Unaudited)
1	Total Income from Operations	9.97	21.20	4.59
2	Net Profit/ (loss) for the period (Before Tax, Exceptional and/ or Extraordinary Items)	0.45	(12.42)	(7.94)
3	Net Profit/ (loss) for the period before Tax (After Exceptional and/ or Extraordinary Items)	0.45	(12.42)	(7.94)
4	Net Profit/ (loss) for the period after Tax (After Exceptional and/ or Extraordinary Items)	0.45	(12.42)	(7.94)
5	Total Comprehensive Income for the period (Comprising Profit/ (Loss) for the period (after tax) and Other Comprehensive Income (after tax)	0.45	(12.42)	(7.94)
6	Paid-up Equity Share Captial (Face Value of Rs.10/- each)	4,017.25	4,017.25	4,017.25
7	Other Equity (Excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year	35		556
8	Earnings Per Share (of Rs.10/- each) for the period (not annualised): Basic & Diluted (Rs.)	0.0011	(0.0309)	(0.0198)

### Notes:-

The turnover/ income is NIL post name change and business activities.

2. The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly & Year to date Financial Results are available on the Stock Exchange website www.bseindia.com and on the Company's website www.escortsfinance.com By Order of the Board

For Invigorated Business Consulting Limited Kamal Sachdeva

Place: Faridabad Date: January 31, 2024

Director DIN: 10364431



# MANKIND PHARMA LIMITED

Registered Office: 208, Okhla Industrial Estate, Phase-III, New Delhi - 110 020, Delhi, India; Tel.: +91 11 4747 6600 Corporate Office: 262, Okhla Industrial Estate, Phase-III, New Delhi - 110 020, Delhi, India; Tel.: +91 11 4684 6700 Email: investors@mankindpharma.com, Website: www.mankindpharma.com, CIN: L74899DL1991PLC044843

Extract of unaudited financial results for the quarter and nine months ended December 31, 2023

(₹ in Lacs except as stated otherwise)

	Consolidated						
S. No.	Particulars	Fo	r the quarter en	ded	For the nine	For the Year ended	
		31.12.2023 (Unaudited)	30.09.2023 (Unaudited)	31.12.2022 (Unaudited)	31.12.2023 (Unaudited)	31.12.2022 (Audited)	31.03.2023 (Audited)
1	Revenue from operations	260,695.89	270,809.90	209,093.03	789,367.54	669,676.60	874,943.30
2	Profit for the period/year before tax	56,232.92	64,098.71	37,898.93	182,778.18	129,395.38	167,123.91
3	Profit for the period/year after tax	45,981.37	51,117.67	29,571.95	146,517.88	101,597.76	130,967.58
4	Total comprehensive income for the period/ year	46,556.60	50,905.98	29,382.74	146,551.79	101,019.09	130,778.83
5	Paid-up equity share capital	N.A.	N.A.	N.A.	N.A.	N.A.	4,005.88
6	Other equity excluding revaluation reserve	N.A.	N.A.	N.A.	N.A.	N.A.	739,516.40
7	Earnings per equity share of face value of ₹ 1/- each - Basic EPS (in ₹) - Diluted EPS (in ₹)			7,		io	
		11.33	12.51	7.09	35.99	24.87	32.00
		11.31	12.49	7.09	35.94	24.87	32.00
3		(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	98

# The key standalone financial information is as under

(₹ in Lacs except as stated otherwise)

The key standardie infancial information is as direct.									
S.	Particulars	Foi	r the quarter en	ded	For the nine r	For the Year ended			
No.		31.12.2023 (Unaudited)	30.09.2023 (Unaudited)	31.12.2022 (Unaudited)	31.12.2023 (Unaudited)	31.12.2022 (Audited)	31.03.2023 (Audited)		
1	Revenue from operations	235,856.62	245,334.52	193,623.10	711,212.27	625,503.15	812,715.32		
2	Profit for the period/year before tax	57,635.16	61,196.24	32,563.69	171,470.71	120,740.31	156,283.66		
3	Profit for the period/year after tax	48,707.33	47,288.44	24,887.32	136,923.99	96,727.00	124,825.80		
4	Total comprehensive income for the period/year	49,399.98	46,932.51	24,606.02	136,991.74	95,870.94	124,339.91		

# Notes:

www.readwhere.com

- The above is an extract of the detailed format of Quarterly Unaudited Consolidated and Standalone Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Stock Exchanges website: www.bseindia.com and www.nseindia.com and also on the Company's website: www.mankindpharma.com.
- The Unaudited Consolidated and Standalone Financial Results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on January 31, 2024.

For and on behalf of MANKIND PHARMA LIMITED

Ramesh Juneja

Chairman and Whole Time Director Place: New Delhi Date: January 31, 2024 DIN: 00283399



LEAD MANAGER TO THE ISSUE

FEDEX SECURITIES PRIVATE LIMITED

B 7, 3rd Floor, Jay Chambers, Dayaldas Road, Vile Parle (East), Mumbai - 400 057, Maharashtra, India

Telephone +91 81049 85249 E-mail: mb@fedsec.in

Investor Grievance E-Mail: mb@fedsec.in Website: www.fedsec.in

Contact Person: Mr. Saipan Sanghvi SEBI Registration Number: INM000010163

FOR DOCMODE HEALTH TECHNOLOGIES LIMITED

On behalf of the Board of Directors

Paulson Paul Thazhathedath **Designation:** Managing Director DIN: 02301881

Date: January 31, 2024 Place: Mumbai, Maharashtra

सं.

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES ON LISTING OR THE BUSINESS. PROSPECTS OF DOCMODE HEALTH TECHNOLOGIES LIMITED.

The Prospectus is available on the website of SEBI at www.sebi.gov.in, the website of the Lead Manager at www.fedsec.in, website of the National Stock Exchange of India Limited at www.nseindia.com and website of Issuer Company at www.docmode.org For details, investors should refer to and rely on the Prospectus including the section titled "Risk Factors" beginning on page 27 of the Prospectus.

The Equity Shares offered in this Issue have not been and will not be registered under the US Securities Act 1933, as amended (the "Securities Act") or any state securities laws in the United States and may not be offered or sold within the United States or to, or for the account or benefit of, "U.S. persons" (as defined in Regulation S of the Securities Act), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act.

The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and Application may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction.

ग्रोवी इंडिया लिमिटेड सीआईएन : L74130DL1985PLC021532 () GROVY Criminal Court, Ludhiana पंजीकृत कार्यालय : 122, प्रथम तल, विनोबापुरी, लाजपत नगर पार्ट ।।, नई दिल्ली–110024 ईमेल आईडी : grovyindia@gmail.com, वेबसाइट : www.grovyindia.com दूरभाष नं: 011-46740000 Ludhiana COMA/ 28678/2019 31 दिसंबर 2023 का समाप्त ।तमाहा एवं ना माह के अलखापराक्षित एकल ।वत्ताय पारणामा का साराश CNR:NO: PBLD03-032587-2019 Poshi: 29-02-2024 31.03.2023 ublication notice for proclamation under section समाप्त तद्नुरूपी तिमाही को समाप्त को समाप्त 82 CRPC Complaint RIVE sec. 138 of n i not पूर्ववर्त्ती वर्ष होनेवाली तिमाही नौ माह Mrs D Marketing Vs. M/s Punjab Machine Tools 337.17 2117.43 608.41 1638.75 Corporation 19.34 126.80 47.46 121.99 असाधारण मदों से पूर्व) Votice To: Said Rehman, Prop Of M's कर पूर्व अवधि हेतु निवल लाभ/(हानि) (आपवादिक एवं/अथवा असाध Punjab Machine Tools Corporation 47.46 121.99 19.34 126.80 मदों के उपरांत) Exhibition Road Comer, Patha Bihar कर पश्चात् अवधि हेतु निवल लाभ/(हानि) (आपवादिक एवं/अथव (M: 06202324535) 16.54 34.84 90.52 96.1 असाधारण मदों के उपरांत) Afternoon if has been proved to the अवधि हेत कल व्यापक आय (अवधि हेत लाभ / (हानि) (कर उपरांत) तथा अ satisfaction of this court that you the 22.04 121.22 44.49 90.92 व्यापक आय (कर उपरांत) से समाविष्ट) accused above named cannot be served in the ordnary way of service. Hence this 333.41 333.41 333.41 333.41 endamation under section 52 CRPC is आरक्षितियां (पुनर्मुल्यांकन आरक्षित छोडकर) पूर्ववर्त्ती वर्ष के लेखापरीक्षित तुलन–पत्र hereby issued against you with a direction 1426.04 में निदर्शितानुसार that you should appear personally before COURT OR 29-02-2024 At 19700 a.m. O within 30 days from the state of publication of this proclamation take natios that, in 1. उपरोक्त सारांश, सेबी (सुचीकरण दायित्व एवं अन्य प्रकटीकरण आवश्यकताएं) विनियमावली 2015 के विनियम 33 के अंतर्गत स्टॉक एक्सचेंजों के पास फाइलबद्ध tofourt of your part to appear as directed विस्तृत त्रैमासिक वित्तीय परिणामों का एक सारांश हैं। विस्तृत त्रैमासिक वित्तीय परिणाम, स्टॉक एक्सचेंज की वेबसाइट अर्थात् (www.bseindia.com) और कंपर्न above the above said case will be heard. की वेबसाइट अर्थात् (www.grovyindia.com) पर उपलब्ध है। and determined as per law, in your 2. उपरोक्त अलेखापरीक्षित वित्तीय परिणामों तथा खण्डवार परिणामों की समीक्षा एवं संस्तृति, लेखापरीक्षण समिति द्वारा 31-01-2024 को आयोजित अपनी बैठक steamor Given under my hand and the की गयी है तथा निदेशक मंडल द्वारा 31-01-2024 को आयोजित अपनी बैठक में इनका अनुमोदन किया गया है। seal of the court. for details logon to:

> THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY. THIS IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE FOR UNITS OR SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA.

कृते ग्रोवी इंडिया लिमिटेड

प्रकाश चंद जालान


डीआईएन : 00475545

https://highcountchd.gov.in/?trs=district\_rr

JMIC Luchiana

ctice&district=ludNana

## PUBLIC ANNOUNCEMENT



स्थान : नई दिल्ली दिनांक : 31-01-2024



# **JNK INDIA LIMITED**

Our Company was incorporated as "JNK India Private Limited", a private limited company under the Companies Act, 1956 in Thane, Maharashtra, pursuant to a certificate of incorporation dated June 14, 2010, granted by the Registrar of Companies, Maharashtra at Mumbai ("RoC"). Pursuant to the conversion of our Company from a private limited company into a public limited company and as approved by our Board on April 12, 2023, and a special resolution passed by our Shareholders at the EGM on April 14, 2023, the name of our Company was changed to "JNK India Limited", and the RoC issued a fresh certificate of incorporation on May 26, 2023. For details of change in the Registered Office, see "History and Certain Corporate Matters - Changes in the Registered Office" on page 180 of the DRHP.

Registered and Corporate Office: Unit No. 203, 204, 205 & 206, Opposite TMC Office Centrum IT Park, Near Satkar Hotel, Thane -West, Thane 400 604, Maharashtra, India Tel: +91 22 6885 8000; Contact Person: Ashish Soni, Company Secretary and Compliance Officer; Tel: +91 22 6885 8000; E-mail: compliance@inkindia.com;

#### Website: www.jnkindia.com; Corporate Identity Number: U29268MH2010PLC204223 NOTICE TO INVESTORS ("NOTICE")

INITIAL PUBLIC OFFERING OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹ 2 EACH ("EQUITY SHARES") OF JNK INDIA LIMITED ("OUR COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ [•] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹ [•] PER EQUITY SHARE) (THE "OFFER PRICE") AGGREGATING UP TO ₹ [●] MILLION (THE "OFFER"), COMPRISING A FRESH ISSUE OF UP TO [●] EQUITY SHARES AGGREGATING UP TO ₹ 3,000.00 MILLION ("FRESH ISSUE") AND AN OFFER FOR SALE OF UP TO 8,421,052 EQUITY SHARES (THE "OFFERED SHARES") AGGREGATING UP TO ₹ [●] MILLION (THE "OFFER FOR SALE"). THE OFFER WILL CONSTITUTE [ • ] % OF OUR POST-OFFER PAID-UP EQUITY SHARE CAPITAL. Potential Bidders may note the following:

a) On November 30, 2023, one of our Promoters, Dipak Kacharulal Bharuka transferred 4,960,000 Equity Shares to Bharuka Family Private Trust ("Trust"), a family private trust managed by Amicorp Trustees India Private Limited as its trustee ("Trustee") established vide a trust deed executed on February 22, 2023 ("Trust Deed"), wherein Dipak Kacharulal Bharuka and his wife Priya Bharuka are the primary beneficiaries, by way of a gift, for no consideration ("Transfer"). Except for Dipak Kacharulal Bharuka, one of our Promoters, Directors and Key Managerial Personnel and Priya Bharuka, one of the members of the Promoter Group of Dipak Kacharulal Bharuka, the Trust is not connected with our Company, our Promoters, our Promoter Group, our Directors, our Key Managerial Personnel, our Subsidiaries, our Group Companies and their respective directors and key managerial personnel.

b) Further, on January 30, 2024, the Trust transferred 4,960,000 Equity Shares to one of our Promoters, Dipak Kacharulal Bharuka, by way of a gift, for no consideration ("Reverse

The details of Transfer and Reverse Transfer are provided below: Date of Transaction/ Name of Name of Transferee/ Nature of Number of Equity Transfer Price per Transfer Shares Transferred Equity Shares (in ₹) Acquirer/Allottee Transfer Transferor November 30, 2023 Bharuka Family Private Trust managed Dipak Kacharulal Bharuka Gift 4,960,000 by Amicorp Trustees India Private Limited January 30, 2024 Bharuka Family Private Trust managed Dipak Kacharulal Bharuka Gift 4,960,000 Nil by Amicorp Trustees India Private Limited

Details of the shareholding of the Trust and Dipak Kacharulal Bharuka set forth below: a) Shareholding of Dipak Kacharulal Bharuka and the Trust in the Company, prior to and subsequent to the Transfer-Pre-Transfer Shareholding

S. Date of Transaction Post-Transfer Shareholding /Transfer No. of Equity Percentage of pre-Offer share No. of Equity Percentage of pre-Offer share capital of the Company (%) capital of the Company (%) Shares Shares November 30, 2023 4,960,000 10.25 Dipak Kacharulal Bharuka Bharuka Family Private Trust managed 4,960,000 10.25 by Amicorp Trustees India Private Limited

b) Shareholding of the Trust and Dipak Kacharulal Bharuka in the Company, prior to and subsequent to the Reverse Transfer-S. Date of Transaction Pre-Transfer Shareholding Post-Transfer Shareholding /Transfer No. of Equity Percentage of pre-Offer share No. of Equity Percentage of pre-Offer share

	ritansiei			Shares	capital of the Company (%)	Shares	capital of the Company (%)
1.	January 30, 2024	uary 30, 2024 Bharuka Family Private Trust managed by Amicorp Trustees India Private Limited		4,960,000	10.25	*	
		Dipak Kacharula	l Bharuka		100	4,960,000	10.25
		BOOK RUNN	ING LEAD MANA	GERS	REC	SISTRAR TO THE	E OFFER
	<b>IIFL</b> s	ECURITIES	DICK	CI Securit	ies	<b>INK</b> Int	time
HEL Convention Limited LCCI Security		tine Limited	Liel	ink Intima India Drivata Limitad			

ICICI Securities Limited IIFL Securities Limited Link Intime India Private Limited C-101, 1" Floor, 247 Park, L.B.S. Marg, 24" Floor, One Lodha Place ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai 400 025 Maharashtra, India Senapati Bapat Marg, Lower Parel (West), Vikhroli West, Mumbai 400 083 Maharashtra, India Mumbai 400 013 Maharashtra, India Tel: +91 22 6807 7100 Tel: +91 810 811 4949 Tel: +91 22 4646 4728 E-mail: jnk.ipo@icicisecurities.com E-mail: jnkindia.ipo@linkintime.co.in E-mail: jnk.ipo@iiflcap.com Website: www.linkintime.co.in Investor grievance e-mail: Investor grievance e-mail: ig.ib@iiflcap.com customercare@icicisecurities.com Investor grievance e-mail: Website: www.icicisecurities.com Website: www.iiflcap.com jnkindia.ipo@linkintime.co.in Contact person: Mukesh Garq/ Pawan Jain Contact person: Namrata Ravasia/ Harsh Thakkar Contact person: Shanti Gopalkrishnan SEBI registration no.: INM000010940 SEBI registration no.: INM000011179 SEBI Registration No.: INR000004058

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the DRHP.

For JNK INDIA LIMITED

Company Secretary and Compliance Officer

Ashish Soni

Place: Mumbai, Maharashtra Date : January 31, 2024

JNK India Limited is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its equity shares and has filed the DRHP with the Securities and Exchange Board of India ("SEBI") and the Stock Exchanges. The DRHP is available on the websites of the Company at www.jnkindia.com, SEBI at www.sebi.gov.in, the book running lead managers, IFL Securities Limited and ICICI Securities Limited at https://www.iiflcap.com and https://www.icicisecurities.com, respectively, and National Stock Exchange of India Limited and BSE Limited at www.nseindia.com and www.bseindia.com, respectively. Any potential investor should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see "Risk Factors" of the DRHP on page 28, when available. Potential investors should not rely on the DRHP filed with SEBI for any investment decision.

The Equity Shares offered in the Offer have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any other applicable law of the United States and, unless so registered, may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Equity Shares are being offered and sold outside the United States in offshore transactions in compliance with Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales are made.

